Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients

Not Recruiting

Trial ID: NCT00186940


This is a multi-center trial for rasburicase in children at high risk of tumor lysis syndrome who have a history of asthma/atopy. The main purpose of this study is to establish the safety of this drug in patients with a history of asthma or severe allergies.

Official Title

A Study of Rasburicase Treatment for Chemotherapy of Malignancy-Induced Hyperuricemia in Patients With a History of Asthma Allergies

Stanford Investigator(s)


Inclusion Criteria:

   - A diagnosis of hematologic malignancy.

   - Existing hyperuricemia or high risk of developing hyperuricemia of malignancy.

   - The treating clinician plans to treat the patient with rasburicase. A patient is only
   eligible for RASALL if the clinician has already decided to use rasburicase.
   Rasburicase should not be given in order to make a patient eligible for this
   non-therapeutic observational study.

   - No prior exposure to rasburicase or other urate oxidase.

   - A history of asthma or significant allergy.

Exclusion Criteria

   - Wheezing or an active hypersensitivity reaction at entry.

   - Hypersensitivity to Aspergillus proteins.


drug: Rasburicase

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
LPCH New Patient Coordinator

New Trial Alerts

Receive email alerts when trials open to patients.